Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Impact of Anticholinergic Burden on the Development of Mild Behavioral Impairment.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2026
Same author

Proteomic identification and validation of novel neuronal EV-based markers for Alzheimer's disease biomarker discovery.

bioRxiv : the preprint server for biology·2026
Same author

Predictors of cognitive resilience in the old-old: An observational study using real-world electronic health record data.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Proteomic profiling of brain organoids and extracellular vesicles identifies early Alzheimer's disease biomarkers and drug response heterogeneity.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Mild Behavioral Impairment: A Population-Based Study.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same author

Nancy Almand Ator, Ph.D. 1944-2025.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026

Related Experiment Video

Updated: Jul 12, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Apolipoprotein E genotype and lifetime cognitive decline.

Nicholas A Kozauer1, Michelle M Mielke, Gary Kwun Chuen Chan

  • 1Division of Geriatric and Neuropsychiatry, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. nkozaue1@jhmi.edu

International Psychogeriatrics
|August 23, 2007
PubMed
Summary

The apolipoprotein E (APOE) genotype is linked to cognitive decline in younger adults, particularly in delayed recall. This association may be masked in older individuals due to survival bias, suggesting a complex relationship over a lifetime.

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Related Experiment Videos

Last Updated: Jul 12, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Area of Science:

  • Neuroscience
  • Genetics
  • Epidemiology

Background:

  • The apolipoprotein E (APOE) gene is a significant genetic risk factor for late-life cognitive decline and dementia.
  • Understanding the longitudinal impact of APOE genotype on cognitive function across the lifespan is crucial for identifying at-risk individuals and developing targeted interventions.

Purpose of the Study:

  • To examine the relationship between apolipoprotein E (APOE) genotype and lifetime cognitive decline over 22 years.
  • To investigate how APOE genotype influences cognitive performance and decline in younger versus older adult cohorts.

Main Methods:

  • A large community-based cohort study followed 818 participants, collecting APOE genotype data from 659 individuals.
  • Cognitive function was assessed using the Mini-mental State Examination (MMSE) and verbal learning tests (immediate recall, delayed recall, word recognition) over four waves.
  • Analyses compared cognitive scores and decline rates between APOE epsilon4 carriers and non-carriers, stratified by age at baseline (<65 vs. >=65 years).

Main Results:

  • APOE epsilon4 carriers exhibited lower cross-sectional cognitive scores on all tested tasks at wave 4 compared to non-carriers.
  • In younger individuals, APOE epsilon4 carriers showed a greater annual rate of decline in delayed recall and MMSE scores.
  • After adjusting for covariates, only the decline in delayed recall remained a significant longitudinal association with APOE epsilon4 carriage in the younger cohort.

Conclusions:

  • An association exists between APOE genotype and decline in delayed recall, and potentially MMSE, over an extended period, specifically in younger individuals.
  • The absence of a significant association in older individuals is likely attributable to survival bias, where individuals with poorer cognitive health may not have survived or participated.
  • While APOE genotype is clearly linked to late-life cognitive decline, its relationship with cognitive decline across the entire lifespan is more complex and age-dependent.